Table 1 Patients’ characteristics (high-density transcriptomic studies)
Patients with early rheumatoid arthritis (n = 21) | |
|---|---|
Baseline biopsies (number) | 21 |
Follow-up (3 months) biopsies (number) | 20 |
Age at baseline (mean ± SD, years) | 51.4 ± 12.8 |
Gender (female/male, number) | 16/5 |
Anti-citrullinated peptide antibodies status (% positive) | 66.7 % |
Rheumatoid factor status (% positive) | 71.4 % |
Disease duration (mean ± SD, years) | 0.5 ± 1.1 |
Disease activity score in 28 joints-CRP in methotrexate group (n = 9) | |
Baseline | 4.51 ± 1.49 |
After 3 months | 3.84 ± 1.61 |
After 6 months | 3.10 ± 1.54 |
Good, moderate, poor responders (number at 3 months) | 2, 3, 4 |
Good, moderate, poor responders (number at 6 months) | 5, 2, 2 |
Disease activity score in 28 joints-CRP in tocilizumab group (n = 12) | |
Baseline | 4.50 ± 1.10 |
After 3 months | 2.35 ± 0.95 |
After 6 months | 2.17 ± 1.14 |
Good, moderate, poor responders (number at 3 months) | 7, 4, 1 |
Good, moderate, poor responders (number at 6 months) | 9, 0, 3 |
Rheumatoid arthritis patients refractory to TNF blockade | |
Baseline biopsies, number | 12 |
Follow-up (3 months) biopsies, number | 12 |
Age at baseline (mean ± SD, years) | 54.6 ± 16.1 |
Gender (female/male, number) | 9/3 |
Anti-citrullinated peptide antibodies status (% positive) | 50 % |
Rheumatoid factor status (% positive) | 41.7 % |
Patients receiving concomitant methotrexate therapy | 100 % |
Disease activity score in 28 joints-CRP at baseline | 5.80 ± 1.32 |
Disease activity score in 28 joints-CRP 3 months after administration of rituximab treatment | 4.48 ± 1.28 |